Renagel Related Published Studies
Well-designed clinical trials related to Renagel (Sevelamer)
Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer
hydrochloride as a phosphate binder in haemodialysis patients: a pilot study. [2012]
Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial. [2011.11.30]
Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. [2011.05]
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. [2011.05]
Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. [2011.03]
Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. [2011.02.02]
Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. [2011]
Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients. [2011]
Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. [2010.12]
Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. [2010.11]
Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. [2010.06.07]
Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia? [2010.04]
A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. [2010.02]
Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. [2009.12]
A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. [2009.12]
Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. [2009.10]
Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. [2009.07]
Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use? [2009]
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. [2008.06]
Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. [2008.04]
Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. [2008.02]
Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. [2008.01]
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study. [2008.01]
Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. [2008]
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. [2007.11]
Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients. [2007.06]
Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing. [2006.09]
Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. [2006.05]
A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. [2006.04]
Sevelamer worsens metabolic acidosis in hemodialysis patients. [2006.03]
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. [2005.10]
Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients. [2005.08]
Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. [2005.08]
Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. [2005.08]
Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. [2005.01]
Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. [2004.06]
Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). [2004.05]
Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. [2004.01]
Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. [2003.12]
The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. [2003.09]
Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. [2003.06]
Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. [2003.03]
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. [2002.07]
Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. [2001.02]
Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. [2001.02]
Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. [2000.10]
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. [1999.04]
A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. [1999.01]
Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. [1998.09]
Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. [1997.01]
Well-designed clinical trials possibly related to Renagel (Sevelamer)
A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. [2011.08]
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. [2011.01]
Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. [2011]
A randomized controlled trial of oral phosphate binders in the treatment of
pseudoxanthoma elasticum. [2011]
Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. [2010.12]
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? [2010.02]
Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. [2009.12]
Vascular calcification and QT interval in incident hemodialysis patients. [2009.11]
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. [2009.10]
[Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost] [2009.04]
Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. [2008.12]
Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results. [2008.10]
K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. [2008.03]
Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. [2007.11]
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. [2007.03]
Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. [2005.05]
Modeling the implications of changes in vascular calcification in patients on hemodialysis. [2005.04]
Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification. [2004.08]
Effect of phosphate binders on supplemental iron absorption in healthy subjects. [2002.10]
Other research related to Renagel (Sevelamer)
Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer
hydrochloride in hemodialysis patients. [2012]
Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. [2011.11]
Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: Results from the French ARNOS study. [2011.10]
Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. [2011.06.24]
Sevelamer use and incidence of peritonitis in peritoneal dialysis. [2011.04]
Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. [2011.02]
Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder. [2011]
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the
treatment of hyperphosphatemia in patients with end-stage renal disease: a US
payer perspective. [2011]
Evaluating the effects of sevelamer carbonate on cardiovascular structure and
function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised
controlled trial. [2011]
[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality]. [2010.11]
Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V). [2010.11]
Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. [2010.09]
Effect of Sevelamer Hydrochloride Exposure on Carotid Intima Media Thickness in Hemodialysis Patients. [2010.08.06]
Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? [2010.03.25]
The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research. [2010.01]
Ten-year experience with sevelamer and calcium salts as phosphate binders. [2010.01]
Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. [2010]
[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients:
effects on vascular calcification and mortality]. [Article in Japanese] [2010]
Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis
patients. [2010]
Does concomitant administration of sevelamer and calcium carbonate modify the
control of phosphatemia? [2010]
A randomized, parallel, open-label study to compare once-daily sevelamer
carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing
in CKD patients on hemodialysis. [2010]
Short-term efficacy of sevelamer versus calcium acetate in patients with chronic
kidney disease stage 3-4. [2010]
Economic Evaluation of Sevelamer versus Calcium-Based Phosphate Binders in Hemodialysis Patients: A Secondary Analysis using Centers for Medicare & Medicaid Services Data. [2009.10.15]
Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. [2009.09]
A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. [2009.08.07]
[Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy] [2009.05]
Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. [2009.05]
Effect of sevelamer hydrochloride on bone in experimental uremic rats. [2009.02]
Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients on Sevelamer Hydrochloride: Which Dialysate Calcium Concentration to Use? [2009.01.14]
Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. [2009.01]
Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. [2009]
Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. [2009]
|
